2023年7月13日 · Our study suggested that this BsAb could specifically bind to MUC1- and CD3-positive cells and efficiently enhance T cell activation, cytokine release, and cytotoxicity. Furthermore, our study demonstrated that this BsAb could potently redirect T cells to eliminate MUC1-expressing tumor cells in vitro and significantly suppress MUC1-positive ...

PM-CD3-GEX: 一种CD3刺激剂、MUC1调节剂药物，由Glycotope GmbH (Glycotope GmbH)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂),MUC1调节剂(黏蛋白-1调节剂)，治疗领域: 肿瘤,内分泌与代谢疾病,呼吸系统疾病，在 …

2023年7月13日 · A high quality of MUC1-CD3 BsAb can be acquired through a standard method. Our study suggested that this BsAb could specifically bind to MUC1- and CD3-positive cells and efficiently enhance T cell activation, cytokine release, and cytotoxicity.

2023年7月13日 · 在这项研究中，我们构建了一种新型 T 细胞接合双特异性抗体 (BsAb)，其靶向 MUC1 和 CD3，具有 Fab-ScFv-IgG 格式。 通过标准方法可以获得高质量的 MUC1-CD3 BsAb。

These findings demonstrate that MUC1-C-3D1/MUC1-C XY017/CD3 BPBS T-cell engager is capable of inducing a potent mobilization of lymphocyte cytotoxic functions against cancer cells and can be developed as a novel therapeutic for mBC.

In this review we present an overview of the antibodies targeting MUC1 in GI cancers, their potential role in immunotherapy (i.e., antibody-drug and radioimmunoconjugates, CAR-T cells), and other novel therapeutic strategies.

The MUC1+CD3 bsAb was synthesized in another work by adopting the variable anti-CD3 antibody TR66 region and anti-TA-MUC1 PankoMab to target MUC1-expressing MCF-7 BRCA cells. As suggested by co-culture analysis, MUC1+CD3 BsAb efficiently enhances the potent anticancer T-cell response while improving cytotoxicity [ 109 ].

1996年9月15日 · For the purpose of establishing a new adoptive immunotherapy for bile duct carcinoma (BDC), we synthesized two bispecific antibodies (BsAbs), MUC1 x CD3 BsAb constructed with MUSE11 (anti-MUC1 tumor antigen) and OKT-3 (anti-CD3), and MUC1 x CD28 BsAb constructed with MUSE11 and 15E8 (anti-CD28) anti …

2021年7月31日 · In this study, we combined two BsAbs to achieve a dual-target therapy strategy of EpCAM + and MUC-1 + with high affinity and specificity. The results showed that the combination of two BsAbs against EpCAM and MUC-1 could inhibit the growth of lung cancer more effectively in cell lines and primary tumors.

2024年10月23日 · go-203 是muc1二聚化的细胞穿透肽抑制剂，其直接结合到muc1胞内结构域的cqcrk区域。go-203通过阻断多种肿瘤类型中的akt途径而具有抗肿瘤效力。 GO-203通过阻断多种肿瘤类型中的AKT途径而具有抗肿瘤效力。